A report on Korea’s donor-skin facial injections raises questions about consent, FDA oversight and early evidence. Here’s what to ask before deciding.
On October 21, 2026, Business Insider published an investigation into South Korea’s growing market for facial injections made from donated human skin.
This is preliminary, product-specific evidence. The combination treatment prevents a clean estimate of the matrix’s separate contribution. The small sample and short follow-up cannot establish lasting benefit or exclude rare or delayed harms.
Business Insider reported that analysts at Yuanta Securities projected South Korean sales of skin-derived injections at $75 million for 2026. That is a forecast rather than a measured final-market total. The outlet also reported that at least 10 South Korean biotech companies were making or planning to introduce these injections.
Those figures establish commercial interest. They do not measure the quality of a cosmetic result or the strength of the evidence behind it.
For a man over 35 considering facial treatment, that distinction matters more than the size of the market. A busy category can produce more product names and promotional claims without making the underlying decision easier. Popularity answers a question about demand rather than whether a particular injection fits your priorities.
Wanting a more polished appearance is a legitimate goal. It does not require accepting every treatment presented as the next stage of aesthetic medicine. The useful question is not whether a product sounds advanced but whether its documented outcomes justify considering it.
The investigation traces a commercial supply chain connecting U.S. tissue donation with South Korean cosmetic products. Business Insider reported that roughly 90% of human tissue used in South Korea is imported, citing the country’s Ministry of Food and Drug Safety.
L&C Bio identified Florida tissue bank Regenerative Biologics as the supplier of skin for its Re2O product. The tissue bank’s CEO told Business Insider that the supplied tissue came from donors who had consented to international and cosmetic use. South Texas Blood & Tissue separately said families could decline cosmetic use or international and research use.
The reporting therefore does not support a blanket claim that donors were unaware of cosmetic applications. The broader ethical question concerns how clearly families understand the commercial arrangements behind donation.
Bioethics scholar Ana Iltis told Business Insider that donors and families may not know how much money changes hands. The Association of Organ Procurement Organizations offered a counterpoint: reimbursements support procurement and donor-family aftercare. Its spokesperson also disputed describing tissue-related income as profit.
These positions deserve to be kept distinct. Authorization for cosmetic use and understanding the financial supply chain are related questions rather than interchangeable ones.
The report also did not establish that cosmetic injections were diverting tissue from burn care or reconstruction. Business Insider said much U.S. skin supplied to South Korea serves traditional medical purposes. L&C Bio said it prioritizes therapeutic supply.
For a prospective patient, the practical issue is transparency. A clinic should be able to discuss the human origin of the material without hiding it behind a broad “regenerative” label. Ask what information is available about donor authorization and how the product can be traced through its supply chain.
No such conclusion follows from the reported deal. L&C Bio told Business Insider that it had signed a contract to deliver at least $60 million of Re2O to the U.S. over five years. The outlet reported that it remained unclear whether the product could be sold there without federal regulatory approval.
The FDA told Business Insider that some products manufacturers claim qualify for a pathway not requiring approval may not meet the applicable criteria. The agency raised questions about donor-skin products that are decellularized and dried before being ground into powder and injected cosmetically.
That is a stated regulatory concern rather than a reported formal ruling that Re2O is illegal. It is also not a finding that the product is unsafe. The unresolved issue is which regulatory requirements apply to the product and its intended cosmetic use.
For U.S. readers, a distribution announcement is not a substitute for product-specific regulatory documentation. Ask the provider to explain the exact status of the product being offered for the proposed use. A commercial agreement and a medical regulatory decision answer different questions.
This distinction belongs in the conversation before a treatment decision. It should not be left to a reassuring reference to overseas popularity.
The reporting supports a set of discussion prompts rather than a validated screening tool. The goal is to obtain understandable information about the proposed product and care arrangement.
Business Insider described treatment in med spas or dermatology clinics but did not establish a specific provider-credential standard. The setting alone does not resolve the questions above.
These prompts also make the consultation more useful to you. Instead of asking whether a treatment is “good,” you can ask which outcome is being proposed and how that outcome was assessed. You can then discuss what would count as a worthwhile result for your own appearance goals.
Keep comparisons with other facial-injection options separate from the appeal of a new label. A product needs an explanation of its own rather than borrowed credibility from another aesthetic category.
The outcomes described in this research concern measured skin parameters rather than energy or physical function. There is no basis here for treating the injection as a health-span intervention.
That leaves room for a straightforward cosmetic decision. You can care about looking rested or feeling more confident in your appearance without asking a facial procedure to stand in for healthy aging. You can also decide that the available information does not meet your standard for proceeding.
For gay men over 35, there is no single appearance goal that makes this treatment relevant. Interest in aesthetic care does not imply anxiety about aging. Choosing not to have an injection does not mean neglecting yourself.
In practical terms, this report calls for a better consultation rather than an automatic change to your daily routine. Collect the product-specific information before treating a booking as the next step. Use the discussion to clarify the desired result and the alternatives that matter to you.
Your broader grooming priorities can remain separate from this decision. An organized appearance routine does not need to expand every time a new injectable category gains attention.
The editorial distinction is simple: commercial momentum belongs in the background while the proposed treatment deserves scrutiny. The useful outcome is a decision you understand rather than participation in a trend.
Treat donor-skin injections as a product-specific medical decision: seek clear documentation on sourcing and regulatory status, then weigh the evidence and alternatives with a licensed professional rather than treating market growth as proof of benefit.
Better measured skin outcomes, not a larger injection market, are the relevant goal; GayFitLab translates aesthetic research into practical guidance for gay men 35+. For readers facing donor-derived treatment claims, this research-led approach helps separate useful skin evidence from beauty marketing without age panic or a prescribed ideal of how a gay man should look.
Stay connected for research-led guidance on fitness, body composition, skin, grooming, vitality, sexual wellbeing, relationships and healthy aging. Clear ideas for gay men 35+ who want to look good, feel strong and age with confidence.
Build habits and systems that support clear thinking, steady energy and long term capacity throughout a demanding career.
explore the Blog
